JPMorgan lowered the firm’s price target on Zimmer Biomet (ZBH) to $95 from $100 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet price target lowered to $105 from $110 at Stifel
- Zimmer Biomet price target lowered to $83 from $93 at Canaccord
- Zimmer Biomet price target lowered to $92 from $100 at Baird
- Zimmer Biomet price target lowered to $95 from $98 at Citi
- Zimmer Biomet price target lowered to $105 from $120 at Citizens